Health
Three lessons from Covid-19 on accelerating biopharma innovation – STAT
Innovation in biopharma research and development being wrought by Covid-19 will improve R&D in cancer and other fields.
The health care research ecosystem has shifted into overdrive in response to Covid-19, sparking unprecedented speed and agility. The economic and public health burdens it has generated demand that we rethink our approach to developing new vaccines and therapies. Researchers are now examining what we can learn from these experiences and more broadly apply this innovation to research and development in the future.
As we look back at the past few months, I see three lessons that health care resear…
Continue Reading
